OBJECTIVE: To measure synovial tissue interleukin-18 (IL-18) expression in patients with inflammatory arthritis, and to identify associations with serum levels, disease activity, and response to treatment. METHODS: Synovial tissue biopsies and serum samples were obtained from patients with early, active, rheumatoid arthritis (RA) (n = 12), undifferentiated seronegative arthritis (SnA) (n = 9), psoriatic arthritis (PsA) (n = 5), and reactive arthritis (ReA) (n = 2) before and one year after introduction of disease modifying antirheumatic drug (DMARD) treatment. Osteoarthritis (OA) tissues were compared. Tissue IL-18 expression was determined after immunohistochemical staining using a semiquantitative scale. Serum IL-18 was measured by enzyme linked immunosorbent assay. RESULTS: Before treatment was started, tissue IL-18 expression was increased in each diagnostic group compared with OA (p<0.05). Tissue IL-18 expression was correlated with serum C reactive protein levels (r = 0.53, p = 0.003) but not with serum IL-18. After DMARD treatment, 12 patients (five RA, four SnA, three PsA) were re-evaluated. Decreases in tissue IL-18 expression were observed in eight, although the trend did not reach significance (p = 0.068). Changes in tissue IL-18 expression were correlated with changes in serum IL-18 (r = 0.62, p = 0.041) and C reactive protein (r = 0.72, p = 0.009). CONCLUSIONS: Synovial tissue IL-18 expression was correlated with disease activity in inflammatory arthritis. After treatment, tissue levels changed in parallel with changes in serum IL-18 and with changes in the acute phase response. These observations support a role for IL-18 in the pathophysiology of inflammatory arthritis.
OBJECTIVE: To measure synovial tissue interleukin-18 (IL-18) expression in patients with inflammatory arthritis, and to identify associations with serum levels, disease activity, and response to treatment. METHODS: Synovial tissue biopsies and serum samples were obtained from patients with early, active, rheumatoid arthritis (RA) (n = 12), undifferentiated seronegative arthritis (SnA) (n = 9), psoriatic arthritis (PsA) (n = 5), and reactive arthritis (ReA) (n = 2) before and one year after introduction of disease modifying antirheumatic drug (DMARD) treatment. Osteoarthritis (OA) tissues were compared. Tissue IL-18 expression was determined after immunohistochemical staining using a semiquantitative scale. Serum IL-18 was measured by enzyme linked immunosorbent assay. RESULTS: Before treatment was started, tissue IL-18 expression was increased in each diagnostic group compared with OA (p<0.05). Tissue IL-18 expression was correlated with serum C reactive protein levels (r = 0.53, p = 0.003) but not with serum IL-18. After DMARD treatment, 12 patients (five RA, four SnA, three PsA) were re-evaluated. Decreases in tissue IL-18 expression were observed in eight, although the trend did not reach significance (p = 0.068). Changes in tissue IL-18 expression were correlated with changes in serum IL-18 (r = 0.62, p = 0.041) and C reactive protein (r = 0.72, p = 0.009). CONCLUSIONS: Synovial tissue IL-18 expression was correlated with disease activity in inflammatory arthritis. After treatment, tissue levels changed in parallel with changes in serum IL-18 and with changes in the acute phase response. These observations support a role for IL-18 in the pathophysiology of inflammatory arthritis.
Authors: Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Wolfgang Vogel; Herbert Tilg Journal: J Clin Immunol Date: 2002-11 Impact factor: 8.317
Authors: B Möller; J Paulukat; M Nold; M Behrens; N Kukoc-Zivojnov; J P Kaltwasser; J Pfeilschifter; H Mühl Journal: Rheumatology (Oxford) Date: 2003-03 Impact factor: 7.580
Authors: C Plater-Zyberk; L A Joosten; M M Helsen; P Sattonnet-Roche; C Siegfried; S Alouani; F A van De Loo; P Graber; S Aloni; R Cirillo; E Lubberts; C A Dinarello; W B van Den Berg; Y Chvatchko Journal: J Clin Invest Date: 2001-12 Impact factor: 14.808
Authors: A Kaser; D Novick; M Rubinstein; B Siegmund; B Enrich; R O Koch; W Vogel; S H Kim; C A Dinarello; H Tilg Journal: Clin Exp Immunol Date: 2002-08 Impact factor: 4.330
Authors: Leo A B Joosten; Timothy R D Radstake; Erik Lubberts; Liduine A M van den Bersselaar; Piet L C M van Riel; Peter L E M van Lent; Pilar Barrera; Wim B van den Berg Journal: Arthritis Rheum Date: 2003-02
Authors: V Pittoni; M Bombardieri; F R Spinelli; R Scrivo; C Alessandri; F Conti; A Spadaro; G Valesini Journal: Ann Rheum Dis Date: 2002-08 Impact factor: 19.103
Authors: M D Smith; D Baeten; A-K Ulfgren; I B McInnes; O Fitzgerald; B Bresnihan; P P Tak; D Veale Journal: Ann Rheum Dis Date: 2005-06-23 Impact factor: 19.103
Authors: Jon Lampa; Marie Westman; Diana Kadetoff; Anna Nordenstedt Agréus; Erwan Le Maître; Caroline Gillis-Haegerstrand; Magnus Andersson; Mohsen Khademi; Maripat Corr; Christina A Christianson; Ada Delaney; Tony L Yaksh; Eva Kosek; Camilla I Svensson Journal: Proc Natl Acad Sci U S A Date: 2012-07-16 Impact factor: 11.205
Authors: Carl Orr; Elsa Vieira-Sousa; David L Boyle; Maya H Buch; Christopher D Buckley; Juan D Cañete; Anca I Catrina; Ernest H S Choy; Paul Emery; Ursula Fearon; Andrew Filer; Danielle Gerlag; Frances Humby; John D Isaacs; Søren A Just; Bernard R Lauwerys; Benoit Le Goff; Antonio Manzo; Trudy McGarry; Iain B McInnes; Aurélie Najm; Constantino Pitzalis; Arthur Pratt; Malcolm Smith; Paul P Tak; Rogier Thurlings; João E Fonseca; Douglas J Veale; Sander W Tas Journal: Nat Rev Rheumatol Date: 2017-07-13 Impact factor: 20.543
Authors: Jeffrey H Ruth; Christy C Park; M Asif Amin; Charles Lesch; Hubert Marotte; Shiva Shahrara; Alisa E Koch Journal: Arthritis Res Ther Date: 2010-06-16 Impact factor: 5.156
Authors: Terence Rooney; Carl K Edwards; Martina Gogarty; Laura Greenan; Douglas J Veale; Oliver FitzGerald; Jean-Michel Dayer; Barry Bresnihan Journal: Rheumatol Int Date: 2009-10-22 Impact factor: 2.631